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Abstract 
      Post-menopausal estrogen deficiency is recognized 
as playing a pivotal role in the pathogenesis of a number 
of age-related diseases in women, such as osteoporosis, 
coronary heart disease and Alzheimer’s disease. There 
are also sexual differences in the progression of diseases 
associated with the nigrostriatal dopaminergic (DA) 
system, such as Parkinson’s disease (PD), a chronic 
progressive degenerative disorder characterized by the 
selective degeneration  of    mesencephalic   dopaminergic 
(DA)   neurons  in  the  substantia  nigra   pars          compacta 
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(SNpc). The mechanism(s) responsible for DA neuron degeneration in PD are 
still unknown, but oxidative stress and neuroinflammation are believed to play 
a pivotal role in nigrostriatal DA neuron demise. In addition, a complex 
interplay between genetic and environmental factors is believed to modulate 
the vulnerability of nigral DA neurons. Estrogen (E2) neuroprotective effects 
have been widely reported in a number of neuronal cell systems including 
nigrostriatal DA neurons, via both genomic and non-genomic effects. Besides 
other mechanisms, E2 modulation of astrocyte and microglia function in a 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD has 
recently emerged. Here we highlight E2 as a multifunctional hormone 
targeting the nigrostriatal DA system during health and disease with a 
particular focus on gender and E2 modulation of innate and adaptive immune 
responses as key factors involved in neuronal vulnerability. Special emphasis 
is given to the cardinal role of glia-neuron crosstalk directing neuroprotection 
vs neurodegneration and the role of E2 in switching astrocyte and microglia 
pro-inflammatory phenotype into a neuroprotective and anti-inflammatory 
state. Specifically, astrocyte and microglia response to the neurotoxin MPTP, 
and in particular the expression of pro-inflammatory mediators, vary 
according to estrogenic status with direct consequences for DA neuron 
survival, recovery and repair. The herein described estrogenic activation of 
glial anti-inflammatory and “protective” functions may provide a means to 
reduce the detrimental effects of neuroinflammation, while promoting cytokine 
activation of astroglial “pro-regenerative” functions. This mechanism might 
represent a compensatory/adaptive response to reduce neuronal vulnerability 
and/or to stimulate the repair process. These findings provide a new insight 
into the protective action of estrogen that may possibly contribute to the 
development of novel therapeutic treatment strategies for Parkinson’s disease. 
 
Introduction 
 The female hormone, estrogen (E2), plays a fundamental role in a 
multitude of physiological processes in mammals, including reproduction, 
cardiovascular health, skeletal growth and bone homeostasis, immune and 
cognitive functions. One key aspect is represented by the critical action of E2 
in dictating gender-specific processes of brain development, differentiation and 
activity [1,2]. Also within the immune system E2 chiefly contributes to the 
generation of the sexually driven immunological dimorphisms [3] and plays a 
pivotal role in the bidirectional crosstalk between the neuroendocrine and 
immune systems [4]. Within the central nervous system (CNS), E2 promotes 
neuron growth, prevents neuronal cell atrophy, and regulates synaptic 
plasticity [1]. Besides other neuronal systems, estrogen is a well recognized 
physiological regulator of nigrostriatal dopaminergic (DA) neurons, during 
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development, in adulthood and during neuronal degenerative processes, such 
as those involved in Parkinson’s disease (PD), a progressive degenerative 
disorder characterized by the selective loss of mesencephalic DA neurons in 
the substantia nigra pars compacta (SNpc) [5].  
 The loss of dopaminergic afferents to the striatum and putamen results in 
extrapyramidal motor dysfunction, including tremor, rigidity, and bradykinesia 
[6]. The mechanism(s) responsible for DA neuron degeneration in PD are still 
unknown, but oxidative stress, excitotoxicity, depletion of endogenous 
antioxidants, reduced expression of trophic factors and dysfunction of the 
protein degradation system are believed to participate in the cascade of events 
leading to DA neuron death [6-10]. Recent evidence clearly indicates that 
neuroinflammatory mechanisms may play an important role in the 
pathogenesis of PD and inhibition of inflammation proposed as a promising 
pharmacological strategy [11-25]. Therapeutic interventions generally consist 
of the management of motor symptoms with either L-DOPA or dopaminergic 
agents, but they don’t delay progression [6]. In man, epidemiological evidence 
suggests that chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) 
reduces risk by about 45% [19,20].  
 In this paper, after a brief summary of gene-environment interactions and  
hormonal interplay in PD vulnerability, the experimental and clinical evidence 
documenting the vital role of estrogen as a survival, neurotrophic and 
neuroprotective factor for the nigrostriatal DA system will be reviewed. The 
importance of both peripheral and central estrogen synthesis and action via 
estrogen receptors, as well as the impact of estrogen deficiency as a risk factor 
for vulnerability to PD is then summarized.  Neuroinflamation will then be 
introduced as a critical hallmark of nigrostriatal DA degeneration and  
estrogen’s influence  on both innate and adaptive immune mechanisms outside 
and within the brain will be discussed. The cardinal role of estrogen in the 
MPTP model of PD will be introduced together with our own studies 
documenting a key role for E2-induced modulation of the astroglial cell 
compartment in nigrostriatal DA neuron protection against oxidative and 
nitrosative stress cascades engendered by MPTP [25]. 
 
Complex gene-environment interactions play a crucial 
role in increasing vulnerability to Parkinson’s disease: 
A pivotal role for hormones of the stress and gonadal 
axes  
 Although several genes that cause certain forms of inherited PD have been 
identified, most cases of PD appear to be sporadic and likely represent an 
interplay between both genetic and environmental influences [26]. Polymorphisms 
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in candidate genes involved                       in dopamine metabolism, mitochondrial function, 
lipoprotein metabolism and xenobiotic detoxification have been described 
[26]. In addition, polymorphisms of inflammatory genes have been also 
reported, including inducible nitric oxide synthase iNOS [27], IL-6, and 
estrogen receptor beta (ER-β) gene [28]. In addition, smoking and pesticides 
affect the probability of developing PD [26,29]. Rural living, dietary factors, 
exposure to metals, head injury, and exposure to infectious diseases during 
childhood have also been suggested to increase risk [23,26,29]. 
 Of particular mention, genetic factors may interact with early life events 
such as exposure to hormones, endotoxins or neurotoxins, thereby influencing 
disease predisposition and/or severity (Fig. 1). In addition, developmental 
exposure to environmental toxins (such as pesticides/herbicides) in concert 
with other environmental (i.e. endotoxins; hormonal dysfunctions) and/or 
genetic “predisposing” factors, may synergistically increase dopaminergic 
neuron vulnerability [22-31]. 
 In particular, two key axes, which are responsible on the one hand for the 
stress response and modulation of inflammation, and on the other, for 
reproductive hormone homeostasis, are involved: the hypothalamic-pituitary-
adrenocortical axis (HPA) and the hypothalamic-pituitary-gonadal (HPG) axis 
[4,22,-25]. The stress hormones glucocorticoids (GCs), the most potent anti-
inflammatory and immunosuppresive agents known, via their cognate 
receptors (GRs), represent crucial vulnerability factors in experimentally-
induced Parkinsonism [22,24,31] via critical neuroendocrine-immune 
interactions [31,32] are of particular interest. Hence, early embryonic life 
exposure to GR antisense RNA in transgenic mice, leading to an abnormal 
response to stressfull, inflammatory and immune stimuli [33-36], dramatically 
increases DA neuron vulnerability to MPTP, via an exacerbation of the 
neuroinflammatory reaction [22,24,31,36,37].  
 Conversely, environmental enrichment can confer resistance to MPTP 
[38], thereby underlying a crucial role for the environment and the HPA axis, 
which is highly sensitive to environmental manipulations [39,40], as critical 
factors involved in nigral DA neurons preservation.  
 We have  proposed that an altered dialogue between the neuroendocrine 
and the immune systems via the HPA axis, during development, may 
irreversibly shape glial cells and «program» long-term effects in the 
mechanisms regulating immune responsiveness to inflammation, thereby 
contributing to individual vulnerability, propensity and predisposition to 
inflammatory, autoimmune and neurodegenerative disorders [22-25,31,36,37] 
(Fig. 1). Developmental bidirectional interactions between the reproductive 
and the immune sytems during peri-natal life depend upon gender and are 
known to dramatically impact on the maturation and function of neuro- 
endocrine  and immune systems, with  potential influences       for predisposition 
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Figure 1. Schematic representation of the impact of perinatal genetic, hormonal and 
environmental interactions on inflammatory glial cell response and individual resistance 
or susceptibility to inflammatory diseases during adult life. Genetic factors (e.g., sex, 
gene mutations, polymorphisms/ susceptibility genes) can interact with maternal 
hormonal factors and external agents to which mother and fetus are exposed (drug 
treatments, bacteria, viruses, endotoxins, and/or environmental toxins such as heavy 
metals or pesticides), to alter the development of the neuroendocrine-immune system, 
in particular the hypothalamic-pituitary-adrenocortical axis (HPA) and the 
hypothalamic-pituitary-gonadal (HPG) axis. The pivotal target of the overall 
interactions is glia, a key component of the neuroendocrine-immune system. Thus, an 
altered dialogue between the neuroendocrine and the immune system during 
development may irreversibly shape glial cells and «program» long-term effects in the 
mechanisms regulating immune responsiveness to inflammation, thereby contributing 
to individual vulnerability, propensity and predisposition to inflammatory, autoimmune 
and neuromental disorders [for details see text]. Within this context, a key component is 
represented by the interactions between the neuroendocrine and immune systems during 
development and the response of the astroglial cell compartment during adult life. 
 
and/or increased vulnerability to various disease entities in adult life, 
particularly noteworthy are  the mutual interactions between the HPA and 
HGA axes [4,41-44]. 
 Importantly, gender and sex steroid background also appear to strongly 
modulate vulnerability to PD, with mechanisms not completely elucidated. We 
have recently emphasized E2 modulation of glial neuroinflammatory reaction 
in MPTP-induced experimental Parkinsonism [22,25]. In particular, by 
assessing temporal correlations between the astroglial cell response to MPTP, 
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endogenous E2 and changes in DA neuron functionality we documented a 
significant contribution of the astroglial cell compartment, and neuron-
astrocyte-microglial crosstalk in E2–induced neuroprotection [22,25]. In the 
following sections the unique ability of estrogen to exquisitely modulate the 
nigrostrial DA system in health and disease will be emphasized. 
 
Estrogen is a multifunctional hormone targeting the 
nigrostriatal dopaminergic system: Menopause and 
E2 deficiency as risk factors for nigrostriatal DA 
neuron demise  
 Female animals are protected from many forms of neurological insults and 
degeneration relative to their male counterpart, whereas loss of endogenous 
estrogens through pharmacological inhibition, surgical ovariectomy, or 
reproductive senescence eliminates this benefit. Likewise, post-menopausal 
estrogen deficiency is recognized as playing a pivotal role in the pathogenesis 
of a number of age-related diseases in women, such as osteoporosis, coronary 
heart disease and certain neurological diseases, including PD. The extensively 
investigated process of normal reproductive decline in women and 
experimental animals, known as reproductive senescence, involves three major 
players : the ovary, the brain and the immune system, and the marked 
alterations in the interactions of these crucial homeostatic systems are 
associated with the increased vulnerability of female gender to a number of 
aged-associated diseases [4,45-47]. Menopause, a permanent cessation of 
female cyclicity in primates, is characterized by the total exhaustion of ovarian 
follicles and is also accompanied by a virtual disappearance of E2 from the 
circulation. A rapid and marked drop in estrogen levels that prevails for the 
rest of life has significant health implications for women, namely increasing 
their risk of obesity, cardiovascular diseases, osteoporosis, cancer and apparent 
psychological distsurbances. Over the past decade the impact of the prolonged 
post-menopausal hypoestrogenic state on the CNS of women has been 
increasingly appreciated. The endogenous ovarian steroid 17β estradiol,  a 
potent neurotrophic and neuroprotective factor is a prime modulator of the 
aging process in the brain [45-47]. A substantial body of evidence clearly 
indicates that the increased vulnerability of aging women to brain injury  may 
be causally related to their reduced blood E2 levels [45-47]. 
 Regarding the nigrostriatal system, a number of epidemiological studies 
have reported that the incidence and prevalence of PD is higher in men than in 
women [48,49]. Post-menopausal E2 deficiency has been reported to cause a 
worsening of Parkinson-related symptoms, whereas the severity of symptoms 
in women with early PD is diminished by the use of E2 [50]. Association 
Estrogen and Parkinson’s disease 231 
between E2 receptor gene polymorphism and PD disease with dementia and 
with age of onset of PD [28], have been reported. These clinical results are 
supported by a body of experimental evidence indicating that the nigrostriatal 
DA system is subject to modulation by E2 in rodents and non human primates 
[5,51]. Thus, the nigrostriatal DA system is exquisitely sensitive to gonadal 
hormone influence and sexual differences are present in several parameters of 
the nigrostriatal DA neurons, as well as in the progression of diseases 
associated with this system [5,51-64]. Indeed, E2 has been defined as a 
neuroprotectant for the nigrostriatal DA system [51]. The neuroprotective 
effects of E2 have been reported against DA neurotoxicity induced by 6-
hydroxidopamine (6-OHDA), metamphetamine, and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) models of PD [58-64].  
 Collectively, the overall summarized results, coupled to a wide variety of 
other findings [64] convincingly document that the nigrostriatal DA system is 
a preferential target of E2, and loss of peripheral E2 at  menopause may 
represent a crucial risk factor for PD pathogenesis. 
 
Local brain estrogen synthesis and aromatase activity 
in neuroprotection: Aromatase down-regulation as a 
critical pre-disposing factor in neurodegeneration   
 Estrogen is synthesized in a number of human tissues. Aromatase, the 
enzyme in steroidogenesis which is responsible for the conversion of 
testosterone and other C19 steroids to estradiol, has been detected in the CNS 
in a wide variety of vertebrate species [65]. In the brain E2 is formed locally in 
neural tissue from the conversion of precursor androgens by aromatase, and 
estrogen may act in a paracrine/intracrine fashion [66,67]. There has been a 
longlasting debate as to whether this enzyme is expressed in glial cells and/or 
neurons. It is now widely accepted that aromatase is expressed both in glial 
cells and neurons as shown  in the mRNA  and protein levels [68,69]. While 
under normal circumstances the expression of aromatse in the CNS of 
mammals appears restricted to neurons, the expression of the enzyme in 
astrocytes is induced by a number of stimuli [69]. One important consideration 
is that different types of brain injury induce in vivo the expression of aromatase 
in reactive astrocytes; furthermore the expression of aromatase by reactive 
astrocytes is neuroprotective, because the pharmacological inhibition of the 
enzyme in the brain exacerbates neuronal death after different forms of mild 
neurodegenerative stimuli [69]. 
 Further experimental and clinical evidence indicate that brain aromatase 
activity may be neuroprotective. Indeed, a neuroprotective effect of estrogen 
and aromatase have been demonstrated with respect to stroke, Alzheimer’s 
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disease and epilepsy [69]. In the brains of female AD patients, total and free E2 
levels are low indicating that local E2 synthesis is impaired in AD brain [70]. 
In addition a significant negative correlation was found between aromatase 
mRNA levels and amyloid plaque density in AD brains [70]. In addition, 
aromatase gene knock out (ArKO) mice showed enhanced hippocampal 
neuron loss in response to neurotoxin compared with Wt mice [70]. 
 Concerning the nigrostrial DA system, during the perinatal period of rat 
brain development aromatase is transiently expressed from embryonic day 17 
(E17) until post-natal day 10 (P10) in the ventral mesencephalon [71]. In 
contrast, aromatase activity in the striatum is detecteable before birth at low 
levels but increases post-natally and persists in adulthood [71,72]. These data 
are also in accordance with the presence of ERs in these specific brain regions 
[73]. Thus, the capacity of estrogen formation is present at distinct phases of 
mid brain development indicating the ability of mesencephalic cells to to 
synthesize estrogens perinatally. Because considerable E2 production can be 
found within the embryonic midbrain, this implies that E2 intrinsically 
synthesized rather than systemic estrogen is the source for the observed 
estrogen developmental effects [64]. Hence, E2 functions as a trophic factor 
helping in the establishment of and stabilization of early DA connections and 
to initiate functional dopamine transmission [64]. Indeed, the developmental 
expression of tyrosine hydroxylase (TH), the rate limiting step in dopamine 
biosynthesis coincides with  transient aromatase expression in the midbrain 
[74], whereas blocking “in utero” aromatase activity with an aromatase 
inhbitor caused a robust inhibition of TH mRNA and protein levels [74]. In 
addition, using cultured midbrain cells,  the ability of E2 to increase TH mRNA 
and protein levels was further documented, an effect reversed by the 
application of the ER antagonist ICI 182,780 [74]. In adult life, however, E2 
formation declines within these areas and peripheral estrogen reaching the 
brain via  peripheral circulation takes over this function [64]. With regards to 
other DA neuronal systems, aromatase activity has been shown to be involved 
in maintaining the functional integrity and survival of hypothalamic DA 
neurons. Hence, in one year-old male ArKO mice, the absence of E2 promotes 
apoptosis in the DA neurons of the arcuate nucleus of the hypothalamus and 
the medial preoptic nucleus, which in turn has important implications for the 
regulation of energy balance and behavioural aspects [75].  
 Together these data document that brain aromatase activity may be critical 
during ontogenic development of the nigrostriatal DA system, whereas in adult 
life circulating E2 influence morphology and functional activity of these 
neurons. On the other hand, given the potent neurotrophic and neuroprotective 
effect of E2 and aromatase expression in reactive astrocytes, the consecutive 
increase in the local production of estradiol in the brain at injured sites, might 
further represent an endogenous paracrine/intracrine means to reduce the 
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extent of neurodegenerative damage [69]. Recent genetic studies also indicate 
that the brain aromatase gene may modify the risk of several diseases, 
including neurological diseases [76].  
 Collectively, the overall findings indicate, therefore, that besides the age-
dependent peripheral E2 deficiency summarized in the previous section, down-
regulation of brain aromatase activity as a result of ageing, genetic defect or 
pharmacological inhibition, may affect predisposition to neurodegenerative 
processes, including PD. 
 
Multiple genomic and non-genomic mechanisms(s) 
are responsible for E2-induced neuroprotection 
 The mechanism(s) by which E2 protect neurons is currently under intense 
investigation and involve receptor- and non receptor-mediated effects. Both 
subtypes, ER-α and ER-β, mediate the effect of E2 in the brain. Both ERs 
belong to the steroid nuclear receptor superfamily, members of which share a 
common structural architecture [77]. Even though the two types of ERs coexist 
in different brain regions, ER-α and ER-β are also found independently in 
other regions [78]. 
 ER-α appears predominantly expressed in  classical estrogen receptor 
target tissues such as the uterus, mammary gland, bone and cardiovascular 
system, whereas ERβ is mainly expressed in non classical tissues such as the 
prostate, ovary and urinary tract. Within the brain ER expression appears 
species-specific [78]. In rodents, the presence of ER-α in brain regions such as 
the hypothalamus, amygdale and hippocampus, indicate a main role  for ER-α 
in estrogen modulation of neuroendocrine functions, autonomic events and 
memory processing, whereas a higher level of expression of ER-β appears to 
be localized in the the basal forebrain and cerebral cortex [78]. 
 Although some groups failed to detect ERs in the striatum or SN of mice 
at either the mRNA or protein levels, recent evidence of a relative abundance 
of ER-β in the SN and ventral tegmental area suggests that this receptor may 
be important in E2 modulation of midbrain DA systems [79-81]. In particular, 
studies carried out in ER-β KO mice indicate the importance of this receptor 
for neuronal survival, since specific degeneration of neuronal cell bodies 
particularly evident in SN was reported in aged ER-β KO mice [82]. 
Furthermore using an ER-β selective antibody ER-β immunoreactivity was 
recently  and primarily localized  to cell nuclei within selected brain regions 
includidng the ventral tegmental area, and the SN [82]. 
 On the othe other hand, it should be mentioned, that differences in 
reported studies may also depend on variations of ER subtypes according to 
the physiological condition studied, including gender and ageing, but also as a 
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function  of the type (acute or chronic) of brain insult. Of special  interest, as 
recalled in the previous sections, the increased expression of aromatase in 
activated astrocytes and the consequent increase in local E2 synthesis in 
selected brain injured areas might have therefore a further impact in specific 
ERs expression of either neuron or glial populations. 
 The mechanism(s) responsible for E2 neuroprotection have been studied in 
a wide variety of neuronal systems including the DA neuronal system, both in 
vivo and in vitro, and have been shown to involve a multitude of direct 
genomic and non genomic-mediated effects, including anti-apototic, growth 
factor-mediated, and antioxidant effects [83-88]. 
 Generally, E2 action takes place through signaling pathways involving the 
canonical activation of nuclear ER. This mechanism is implicated in the 
regulation of gene expression and requires direct interactions with palindromic 
sequences in the promoter region of target genes [89]. Estrogen bound-ER 
translocates into the nucleus and in conjunction with co-activators and co-
repressors modulates gene expression. Additionally, non classical signalling 
(also termed non-genomic, rapid estrogen effect) involving extranuclear ERs 
(cytoplasmatic, plasma membrane-attached, and mitochondrial-located) plays 
an important role  in mediating physiological estrogen effects [64]. Often, the 
activation of such alternative, non-nuclear ER-dependent pathways entails the 
stimulation of other intracellular signalling cascades such as the MPA-kinases, 
PI3-kinase, CaCaM-kinase, and protein kinase . Interestingly, ER-ligand 
complexes are reported to regulate the activity of NF-KB, an important 
transcriptional regulator of immune function (as discussed in the next 
sections). The exact molecular mechanisms of nonclassical estrogen signaling 
are not fully clarified, it seems apparent that classical ERs located at different 
intracellular sites are coupled directly or through specific adaptor proteins to 
these signalling cascades [89]. While some evidence reveals the requirement of 
ERs in estrogen mediating neuroprotection, the differential role of each 
subtype is not completely elucidated. 
 Using the MPTP mouse model which produces striatal DA denervation 
comparable to PD, the neuroprotective effects of 17-β estradiol and the 
mechanisms implicated in these effects have been studied by a number of 
laboratories [60-64]. Evidence from a number of experiments carried out in 
vivo indicate a genomic mechanism of action to explain the beneficial effects 
of estradiol on dopaminergic neurons. Indeed, the protection obtained with E2 
was only obtained with the β-isomer, while 17-α treatment did not afford 
neuroprotection [62]. Using chronic treatments with ERα and ERβ agonists in 
neuroprotection against MPTP D’Astous et al. have pointed to ERα as 
critically implicated in protection against MPTP-induced DA neurotoxicity 
[62]. In female MPTP-treated mice, endogenous levels of E2 or exogenous E2 
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administration of ovariectomized females have protective effects on nigrostriatal 
DA neurons [25 and further sections]. Rat mesencephalic neurons cultured in 
an E2-containing medium are resistant to apoptosis and neuronal injury, and 
this effect is blocked by the ER-antagonist ICI 182,780 [87,88]. Conversely, by 
using a coculture model of embryonic mesencephalic neurons and mesencephalic 
or striatal astrocytes, the crucial participation of astrocytes in E2 neuroprotective 
effect against serum deprivation-induced cell death was clearly documented, 
suggesting indirect glial-mediated effects of the hormone [25].  
 Mounting evidence clearly indicates that besides the multitude of E2-
mediated effects in exerting neuroprotection, estrogen’s anti-inflammatory 
mechanism(s) may play an important role in the MPTP mouse model of PD [25]. 
The central role of gender and estrogen in dicating major estrogen-dependent 
differences in both innate and adaptive arms of immunity will then be 
summarized. Indeed, involvement of E2 modulation of glial neuroinflammatory 
reaction in the MPTP model of PD has recently emerged [22,25].   
 
Gender, E2 estrogen and sex dimorphism in innate 
and adaptive immune responses: Implications for 
neuronal vulnerability  
 The incidence and severity of human diseases is known to vary between 
sexes. For example autoimmune diseases are generally more common in 
females than in males and are most marked in women of childbearing age [90]. 
It seems apparent that susceptibility to autoimmunity is expressed at the time 
of puberty. Hormonal changes occurring at puberty induce fundamental 
biological differences that persist throught life, thus contributing to the 
variable onset and progression of disease in males and females [3,91]. Sex-
related differences in disease susceptibility have also been observed in several 
mouse models of infectious and autoimmune diseases and may be related to 
differences in the expression patterns of immune response genes. Indeed, 
immune responses are sexually dimorphic, both in type and magnitude and 
gender and the sex steroid hormonal milieu play a central role in the regulation 
of innate, cell-mediated and humoral immune responses outside the brain, 
thereby chiefly contributing to the development and/or severity of some 
autoimmune diseases such as lupus, multiple sclerosis (MS), Rheumatoid 
arthritis (RA), and Graves’s disease [91]. Two general systems of immunity to 
infectious agents have been selected during evolution: innate (natural) 
immunity and acquired (adaptive or specific) immunity. The innate immune 
system uses proteins encoded in the germline (on macrohages, mast cells, 
dendritic cells and natural killer cells) to recognize conserved products of 
infectious non-self (i.e. microbial pathogens). In contrast to this relatively 
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inflexible system is the almost infinitively adaptable immune sytem of 
lymphocytes [90]. These two systems are known to closely interact with each 
others: for example cellular and soluble components of innate immunity help 
the adaptive immune response to select and respond to appropriate antigens. Of 
special importance, recent evidence clearly indicates a sexual dimorphism in 
innate and adaptive immune response genes as a function of puberty, 
implicating the changing sex steroid hormone milieu as a key factor in 
remodelling immune functions with the result that sexual dimorphism in 
immunity is permanently established  in adult life [90]. For example, in both 
experimental animals and in humans, stimulus activated immunity is greater in 
females than in males , and antigen-presenting cells are more effective in 
females [91]. 
 The effect of E2 on immune cells and estrogen’s influence on immune 
responses have been investigated both in vitro and in vivo. In vivo 
experimental studies indicate that E2 influences many different cell types either 
directly or indirectly, including B cells, T cells, macrophages, and NK cells, 
stromal cells, and endothelial cells [91]. The in vivo effects of E2 in immune 
parameters include altered cytokine production, cell differentiation, and 
expression of adhesion molecules  [92,93]. Additionally, there is evidence that 
E2 increases Th2 type cytokines and accordingly decreases cell-based 
immunity in both animals and human models [92-94].  
 In terms of local brain inflammation, this pattern of immune regulation 
would suggest a decrease in the expression of proinflammatory cytokines and a 
decrease in cell-mediated immunity. Many published reports have shown that 
physiological levels of E2 significantly decrease microglia superoxide 
production, nitrite release or phagocytosis in response to stimulation by LPS, 
IFN-γ, MPTP intoxication, or  the HIV protein [25,95-98]. The multifaceted 
regulatory effects of estrogens can be appreciated when studying the effects of 
estrogens upon microglial antigen presentation and T cell activation, documenting 
the hormonal ability to significantly decrease components of adaptive immunity, 
thereby importantly influencing microglia-T cell dialogue [99]. 
 It should be underlined that the effects of  E2 can be direct effects on 
immune cells and/or modulate immune functions via neuroendocrine-immune 
interactions, also modulation of the HPA axis [see previous sections]. In 
addition, the effects of E2 are, both dose- and cell-type specific on immune 
cells and depending on the specific physiological/experimental condition, E2 
can act in both a pro-inflammatory and anti-inflammatory manner.  
 It seems important to recall that in in autoimmunity, Th1/Th2 balance and 
the activation of effector T cell subsets are often critical for the progression or 
the remission of disease, and E2 might play a decisive role in changing the 
plasticity of these cells to drive the immune response towards the protection 
against disease. Thus sex steroids shift T helper cells towards a Th2 phenotype, 
Estrogen and Parkinson’s disease 237 
and cytokines produced by Th2 cells generally suppress EAE [94]. Indeed, 
ERs are present in T cells, macrophages and dendritic cells at all stages of 
differentiation, and direct E2 modulatory effects have been demonstrated.  It is 
worth noting that E2 can potentiate the production of anti-inflammatory Th2 
cytokines, IL-10 and TGF-beta, in antigen-specific T cells, resulting in full 
protection against EAE. Coupled to the recently reported effect of E2 in driving 
the expansion of the “regulatory” T cell compartment [100], these data clearly 
suggest the possibility that E2 may dampen inflammation by directly 
influencing Th1/Th2 balance. It is still not clear, however, whether a similar 
mechanism is operating within the CNS. In fact, signalling from activated cells 
in the periphery to the brain might be also influenced by E2. Neuroimmune 
signalling involves besides others, neuroendocrine-immune interactions, 
(especially the stress axis), NO, circulating cytokines, which interact with 
brain endothelium and macrophage populations in the brain, and in turn, these 
signals are passed on to particular neuronal populations leading to mild and 
chronic brain cell inflammation. For some neurodegenerative diseases, a 
correlation between ongoing central and peripheral inflammation and increased 
susceptibility to  neuronal death has been clearly demonstrated [23]. 
 Significantly, the onset of menopause has been associated with a 
spontaneous increase in cytokine production, specifically TNF-α and the 
interleukins IL-1 and IL-6. Moreover, cytokines levels are reportedly lower in 
post-menopausal women [101] on hormone replacement therapy  and in 
estrogen-treated ovariectomized mice compared to untreated controls. Within 
the brain, age-related increases in glial activation as well as age-related 
increase in cytokines and their receptors documented by histology and gene 
expression analysis indicate a widespread inflammatory response [102,103]. 
Aging is also associated with functional alterations of the blood brain barrier 
(BBB) [104], which may also result in increased permeability with serum 
leakage and leucocyte infiltration into the neuronal parenchyma. It seems also 
important to underline that besides age-induced pro-inflammatory status, pre-
existing inflammatory conditions, such as giant cell artritis and systemic lupus 
erythematosus, increase predisposition to neurodegenerative diseases, as do a 
range of acute and chronic infections, principally respiratory [23]. 
 Collectively, these data indicate the ability of E2 to powerfully modulate 
both innate and adaptive immune mechanisms outside and within the brain. 
Although E2 modulation of immune homeostasis is a complex phenomenon 
with E2 playing a dual pro- and anti-inflammatory role, the process of ageing 
and estrogen deficiency may alter the Th1/Th2 balance, with an increase in 
pro-inflammatory status. In addition E2 deficiency, as reviewed in the next 
section may impact on astrocyte-microglial dialogue, with important 
implications for neuronal vulnerability to a number of acute and chronic brain 
insults/conditions, including PD. 
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Neuroinflammation, Parkinson’s disease, glia and 
hormones 
 Accumulating evidence clearly suggests a pivotal role for glia and neuron-glial 
crosstalk both in the adult and aging brain and E2 has been implicated in the 
modulation of both astrocytes and microglial cell function . In the central nervous 
system (CNS), astroglial cells are recognized  as playing active roles in both health 
and disease states and in influencing the devolpment of the brain’s response to a 
variety of insults [23]. Astrocytes which represent the major glial population and 
microglial cells, like other tissue macrophages, are key components of the 
neuroendocrine-immune axis and, as such, are responsive to endocrine, neural and 
immune factors. In particular, astrocytes, and macrophages/microglial cells express 
hormone receptors (i.e. glucocorticoid receptors, GRs and estradiol receptors, 
(ERs), and are both a source of and target for cytokine, growth and neurotrophic 
factor activities in the brain [22,24,25].  
 Although developmental and constitutive functions of the majority of these 
immunoregulatory molecules in the physiology of the normal, immune 
privileged CNS are still not generally accepted, when CNS homeostasis  is 
disturbed as a result of a trauma, stroke, ischemia, infection or degenerative 
processes, certain cytokines increase, as a result of blood-brain-barrier 
disruption, or from local synthesis by invading immune cells. Then, most, if 
not all neuropathologies are associated with glial cell activation and reactive 
gliosis recognized as a universal hallmark of both acute or chronic damage to 
the CNS [23]. Thus, activated astrocytes and microglia serve as endogenous 
sources of various cytokines involved in the orchestration of cellular responses 
aimed at rapid re-establishement of tissue integrity and subsequent repair [23]. 
Release of products of activated glia are thought to be important for initiating 
and guiding the infiltration of immune cells and for coordinating their 
activities in the brain tissue. While glial responses may be considered 
beneficial mechanisms, when local production of cytokines exceeds the 
appropriate range, cytokine-mediated neurotoxicity may lead to severe 
neuronal damage [105-109]. Activated microglial cells are also important 
participants in local cell-mediated immunity, as activated microglia are not 
only phagocytic, but are also potent sources of reactive oxygen and nitrogen 
species and excitotoxins.  
 
 Hence, a wide variety of inflammatory mediators once thought to be 
restricted to peripheral immune responses are now considered to be central to 
the pathogenesis of major neurodegenerative diseases. A full innate immune 
system (e.g. complement system, scavenger receptors, Toll-like receptors) has 
been described in the CNS and is thought to be an extremely efficient system 
to fight against invading pathogens and toxic cell debris. There is abundant 
evidence that a number of proinflammatory mediators, such as cytokines, and 
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inflammatory-associated factors such as cycloxygenase-2 (COX-2) and 
inducible-nitric oxide synthase (iNOS), are elevated in the CNS or cerebrospinal 
fluid of Huntington’s disease (HD), Alzheimer’s (AD), PD, multiple sclerosis 
(MS) and amyotrophic lateral scelrosis (ALS) patients [23].With regard to PD, 
the first evidence for the involvement of inflammation in PD dates back to 1988, 
when McGeer and coworkers described the up-regulation of major 
histocompatibility complex (MHC) molecules in PD brains. Later, Mogi and 
coworkers reported increased levels of beta2-microglobulin, the light chain of 
MHC, in the striatum of PD patients [17,18]. Accumulation of ROS, NO, COX-2 
products and pro-inflammatory cytokines (including TNF-α, IL-1β and IFN-
gamma) in the SN of PD patients further supported the hypothesis that a state of 
chronic inflammation characterizes the PD brain [11-17]. Confirming a role for 
cytokines, inactivation or genetic ablation of TNF-α receptors attenuated cell 
death in the MPTP model of PD [13-17,23]. NOS also seems important, as 
shown by demonstration of a cytokine/CD23-dependent activation pathway of 
iNOS, and by the association between PD and NOS polymorphisms [11,27]. 
COXs also appears to play a role, as shown by increased COX-2 expression in 
the SN of PD patients [23]. Epidemiological evidence has shown that chronic 
NSAIDs reduce the risk of PD by about 45% [20]. On this basis, several studies 
have been carried out in the MPTP model of PD with non-selective and selective  
COX-blockers. However, discrepancies between these studies (likely depending 
on use of different administration protocols and in vivo modalities of MPTP 
treatment) make it difficult to draw any conclusion. Several other different 
treatments, such as immunological approaches, use of peroxisome proliferators 
activator receptor gamma agonists (PPARγ), or compounds containing the basic 
morphine, or flavonoid/phenolic structure proved to be beneficial [23].  
 Collectively, these findings point to neuroinflammation as a therapeutic 
target in PD neurodegeneration, with astrocytes and microglia being key 
players in this scenario. On the other hand, in view of the dual 
destructive/neuroprotective role of activated astrocytes and microglia, the 
manipulation of glial beneficial and pro-regenerative capacities appears central 
in providing novel therapeutic opportunities for PD [23-25]. Consequently, the 
active search for endogenous and exogenous  astroglial “regulators” in PD 
appears of prime importance.  
 
Astrocytes, microglia, hormones and the MPTP 
model of PD: A pivotal role for estrogen in 
modulating neuron-glia crosstalk  
 Besides others, one endogenous glial regulatory feedback mechanism may 
be represented by hormonal background, in particular estrogens are known 
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regulators of astrocytes, macrophage/microglial and endothelial cell function 
[22,24,25]. In addition, infiltrating T cells and peripheral macrophages are 
critically modulated by the sex steroid hormone background [4]. There are also 
crucial interactions between the stress hormones and E2 in modulating the 
response of inflammation [see previous sections].  
 There is abundant evidence that cultured astrocytes and microglia 
possess estrogen receptors [69]. A number of laboratories have investigated 
the effects of estrogens in LPS-stimulated astrocyte, macrophage or 
microglial cells. Of major interest, estrogens are potent inhibitors of 
inducible nitric oxide (iNOS)-derived NO in activated astrocytes and 
macrophage/microglial cells [22,25,95-99, 110]. Consistently, the primary 
sex steroid hormone, E2, may play an active role under in vivo conditons in 
which increased CNS levels of cytokines would have several adverse 
consequences. In fact, during inflammation, it seems highly possible that a 
sophisticated interplay between hormones of the stress and reproductive axes 
[22,24,25,31,37] participates to the temporal and spatial correct expression 
of iNOS/NO in different organs and tissues, leading to the elimination of 
inflammatory agents with minimal tissue damage . 
 It is worth noting that within the brain, E2 via either ER-alpha and/or ER-
beta, has been shown to exert anti-inflammatory activity on activated 
macrophages and activated microglial cells in vitro, as revealed by the 
prevention of lipolisaccharide (LPS)-induced production of pro-
inflammatory cytokines including TNF-alpha, iNOS-induced NO, COX-2, 
prostaglandin-E2 (PGE2), and metalloproteinase-9 (MMP-9) [95-99]. Most 
importantly, E2 can interact with with the transcription factor NF-kB, a key 
regulator of inflammatory responses [98]. Together with the recently 
described E2 effects of in microglia-T cell dialogue [99], this information 
clearly emphasizes E2 modulation of brain immune homeostasis as a 
determining factor for dictating neurodegeneration on neuroprotection. 
 MPTP is a known neurotoxicant inducer of parkinsonism in human 
patients that has subsequently been modelled extensively in mice as well as 
non human primates [8,9]. MPTP crosses the blood brain barrier and is 
subsequently converted to the neurotoxic metabolite MPP+, a substrate of the 
dopamine transporter (DAT). Astrocytes represent a primary locus for MPTP 
metabolism, and experimental data have clearly documented a key role for 
glial cells in MPTP metabolic activation and MPP+ delivery into the 
extracellular compartment [8]. Once inside DA neurons, MPP+ inhibits 
complex I of the mitochondrial electron transport chain, resulting in ATP 
depletion and subsequent neuronal death (Fig. 2). This energy crisis initiates 
a chain of events culminating in the inability to release a sufficient amount of 
dopamine, locomotor deficits, and ultimately apoptosis of tyrosine 
hydroxylase-positive (TH+) neurons in the SN [10]. Although the sequence 
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of events is not clearly understood, MPP+ toxicity stimulates the generation 
of oxygen-free radicals, activates astrocytes and microglia to produce a 
number of pro-inflammatory cytotoxic mediators, such as cytokines and NO 
(Fig. 2). 
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Figure 2. A schematic representation of detrimental and beneficial inflammatory pathways in 
PD. DA neurons in the substantia nigra pars compacta (SNc) represent a preferential target for 
inflammatory stressors, due to enzymatic and non enzymatic autooxidation of DA generating 
H2O2, to the high toxicity of DA metabolites, and  the interactions between iron (which is 
highly concentrated in SNc) and H2O2 in   the Fenton reaction, leading to highly toxic radicals. 
Injury of these neurons, as a result of specific chemical insults (e.g., MPTP), and/or a 
combination of genetic/environmental factors (viruses, endotoxin, pesticides, susceptibility 
factors) leads to marked glial cell activation. MPTP is metabolized by astroglia to 1 methyl-4-
phenylpyridinium (MPP+) which is concentrated in DA neurons. Here it inhibits cellular 
respiration, generates oxygen-free radicals and NO and initiates a cascade of cytotoxic events 
culminating in reduced DA release, locomotor deficits, and ultimately cell death by apoptosis. 
Astrocytes, which express glutathione at high levels, can protect neurons by scavenging 
radicals and glutamate, by harboring receptors for endogenous anti-inflammatory molecules 
(such as GCs and E2), by providing energy support, trophic factors, «protective» cytokines and 
possibly by stimulating repair processes. On the other hand, under conditions of chronic 
inflammatory stress, activated astrocytes and microglia may become dysfunctional and over-
express a variety of cytoyoxic mediators eventually resulting in DA neuron death [see text, for 
details]. The hypothetical role of endogenous glucocorticoids (GCs) and estrogens (E2) in 
“switching” the “harmful” into a “beneficial, protective” glial phenotype, is illustrated. 
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 Consequently, oxidative stress may be linked to other processes such as 
mitochondrial impairment, inflammation, excitoxicity and the toxic effects of NO 
[8-10,14]. NO can promote oxidative damage to macromolecules including cellular 
proteins implicated in PD pathogenesis such as tyrosine hydroxylase (TH) and 
alpha-synuclein. Then, MPTP intoxication triggers both oxidative and nitrosative 
cytotoxic cascades (the “Mr Hyde” face of glia) largely contributing to nigral DA 
neuron demise. Astrocytes are known to play a central role in the antioxidant 
defense of the brain and to exert a variety of neuroprotective functions. Astrocytes 
scavenge reactive oxygen species (ROS) released by neurons and remove 
glutamate from the extracellular space, thereby reducing the exposure of NMDA 
receptors to this excitatory aminoacid; they produce factors that induce anti-
oxidant enzymes, and express crucial neurotrophic molecules, regulating growth, 
differentiation and survival of neurons, as part of the bidirectional, neuronal-glial 
interactions [111-116]. In particular, fetal mesencephalic neurons in culture are 
extremely vulnerable to serum deprivation [111] or damaging compounds such as 
peroxynitrite, as compared to cultured glial cells, whereas interaction between 
astrocytes and neurons has been variously demonstrated to exert striking 
neurotrophic, differentiation and neuroprotective effects [25]. 
 Glial cells play a pivotal role in all MPTP-toxic mechanisms: a. they 
contribute to H2O2 production (via the MAO-B-dependent dopamine and 
MPTP metabolism); b. they represent a primary locus for H2O2 and reactive 
nitrites scavenging; c. they provide energy support for neurons in conditions of 
metabolic stress; d. they increase GSH export via up-regulation of Mrp1 efflux 
pump [117]; e. they exert “anti-inflammatory” effects via GR and ERs 
activation and down-regulation of iNOS/NO and NF-kB antagonism [25]; and 
f. they protect against NMDA receptor activation by the active uptake of 
glutamate. However, an imbalance of oxidative and nitrosative cascades 
triggered by MPTP may damage astrocytes/impair glial functionality, in that 
astroglial cells may become less efficient and loose their defensive and 
neuroprotective capacities [25] (Fig. 2).  
 Together, these findings clearly implicate both astrocytes and microglia in 
the neurotoxic response to MPTP, the potential role of E2 in “switching” the 
“harmful” into a “beneficial, protective” glial phenotype helping nigrostriatal 
DA neuron rescue will be then discussed in the next sections. 
 
The estrogenic status modulates the response of the 
glial cell compartment to the neurotoxin MPTP: 
Implications for nigrostrial neuron vulnerability to 
PD 
 As in normal menstruating women, in normal cycling female rodents, 
fluctuations in plasma E2 levels occur. The cyclic changes in plasma E2 have 
been reported to modulate structural parameters in various brain regions. In 
Estrogen and Parkinson’s disease 243 
particular, region-specific changes of astrocyte and microglia morphology, cell 
number and or immunoreactivity, have been reported to occur, in vivo, as a 
function of gender and the estrous cycle, aging, gonadal hormone deprivation 
and E2 replacement [118-123]. In addition, sex steroids, in particular E2, have 
been demonstrated to play a major role in modulating changes of glial 
reactivity, and/or proliferation occurring after brain injury [69]. In female 
rodents, various parameters of nigrostriatal system functionality, including 
dopamine concentration, dopamine uptake sites and DA1 receptor density, 
have been shown to vary according to the phases of the estrous cycle (see 
previous sections and Introduction).   
 Based on this literature, the endogenous hormonal status at the time of 
injury may differentially impact on MPTP-induced DA toxicity and/or on the 
ability of nigral neurons to recover. Hence, changes in astrocyte and microglia 
cell function may underlie the neurochemical and morphological alterations of 
nigrostriatal DA neurons as a result of estrogen cyclic variation, as well as 
after estrogen loss and estrogen replacement. We recently addressed whether 
changes in estrogenic status might alter the astroglial response to MPTP 
underlying estrogen neuroprotection against nigrostriatal DA neurotoxicity 
[25]. To this end, temporal changes in different indices of glia reactivity 
(immunocytochemistry and generation of iNOS-derived NO) and DA neuron 
functionality (striatal dopamine and its metabolites) were assessed after 
injection of the neurotoxin, MPTP [25], at proestrous or estrus corresponding 
to high and low plasma E2 levels, respectively, after bilateral ovariectomy 
(OVX, performed 2-3 weeks before MPTP treatment), both in the absence or 
the presence of a concomitant treatment with 17-beta (E2, 1 ug/day) or 17-
alpha (1 ug/day) estradiol. In accordance with our previous studies [31], time-
course analysis of the effect of MPTP on the astroglial cell compartment 
indicated that early (1 day) after MPTP treatment, immunolabeling for GFAP 
started to increase in striatum and midbrain of all MPTP-treated groups, but 
such an increase was different according to the estrogenic status [25]. Lowest 
astrocyte reaction was observed in intact female mice treated with MPTP at 
proestrous, corresponding to the phase of highest E2 serum levels, or in OVX 
mice supplemented with E2, whereas maximal astrocyte hypertrophy was 
observed in E2-deprived (OVX) mice, when plasma E2 levels were almost 
undetectable [25]. Induction of a microglial reaction in the denervated striatum 
and SN of female mice was also earlier and sharper in OVX as compared to 
intact MPTP-treated mice. In addition, one day after MPTP injection in cycling 
females at proestrus, iNOS-IR was weak. By contrast, in OVX mice, a strong 
iNOS-IR signal was localized in both the striatum and SN in both GFAP-IR 
and GFAP-negative round-to-oval shaped cells, identified as activated 
macrophages/microglia [25]. Accordingly, up-regulation of the nitrosative 
stress foot print, nitrotyrosine, and NADPH-diaphorase were revealed in the 
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SN of OVX, as opposed to intact mice at this early time-point. In addition, 3 
days after MPTP, a significant increase in GFAP-IR astrocytes and TH-IR 
neuron death by Terminal deoxynucleotidyl transferase-mediated 2'-deoxy-
uridine-5'-triphosphate nick end labelling (TUNEL), was observed in estrogen 
deprived, but not intact mice [25]. By contrast, treatment with E2, but not 17-
alpha estradiol, sharply inhibited iNOS-IR and decreased TUNEL and 
NADPH-diaphorase reactions in both the striatum and SN [25]. 
 Collectively, the findings indicate that cyclic fluctuations of plasma E2 
levels importantly impact on the glial response to MPTP in female mice, with a 
significant reduction of astrocyte, microglial and iNOS nigrostriatal activation 
when the neurotoxin is administrated during maximal estrogenic activation, 
whereas E2 deficiency as a result of OVX sharply increases all indices of glia 
activation which is accompanied by increased nitrosative stress and 
programmed cell deah of both nigral astrocytes and DA neurons, confirming a 
key role for endogenous E2 in dampening the harmfull glial reaction while 
protecting astrocyte-mediated beneficial effects [25]. 
 
Estrogen deficiency up-regulates microglial iNOS/NO 
response to MPTP: Implications for the demise of 
nigrostriatal DA neurons  
 A number of studies including our own demonstrated a determining role 
for macrophage/microglia iNOS/NO response (measured by its decomposition 
product nitrite) to MPTP-induced DA neurotoxicity [24,25,31]. The hypothesis 
was put forward that estrogen deficiency-induced increase in brain nitrinergic 
status/sensitivity may impact on DA neurotoxicity induced by MPTP. 
Evaluation of the effect of the estrogenic status on NO generation from brain 
macrophage/microglial cells isolated at different time-intervals after MPTP 
intoxication, and correlation of those levels with decreases of striatal dopamine 
implicated such a mechanism [25]. Indeed, although we found that in all mice 
groups, microglial nitrite generation increased as a result of MPTP injection in 
a time-dependent fashion, such increases were however significantly different 
according to estrogenic status and preceded the decrease of DA and its 
metabolites. Consequently, as early as after 6 hrs from MPTP, OVX mice 
exhibited a 4- to 5-fold increase in nitrites as compared to intact estrous, 
proestrous mice or OVX mice treated with E2, but not 17-alpha estradiol [25]. 
It should be  noted that decreases of striatal dopamine and its metabolites 
(DOPAC+HVA) were first observed 24 h after MPTP, and that such decreases 
were far greater in OVX (-68 and –61%, respectively) as compared to estrus    
(-42 and –38%), proestrus (-28 and –24%), or OVX mice treated with E2 (-19 
and –17%), indicating exacerbation of DA neurotoxicity as a result of ovarian 
hormone withdrawal, and a greater protection afforded by the hormonal 
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background of proestrus [25]. Accordingly, within the intact mice group, 
between 6 and 24 h, microglial nitrite levels increased, but such levels were 
significantly (p<0.01) higher in mice treated with MPTP at estrus, as compared 
to mice at proestrous, indicating that endogenous estrogenic status sharply 
modulates microglia functional iNOS/NO response to MPTP. In addition, 
higher microglial NO levels of OVX mice preceded the greater depletion (-
86%) of striatal dopamine and synaptosomial [3H] dopamine uptake (almost 
25% of controls) measured 11-28 days after MPTP, as opposed to intact mice 
showing a significant degree of functional recovery ([3H]dopamine uptake: 
almost 67% of control). Thus, proestrus E2 levels, or exogenous E2 
administration are associated with down-regulation of MPTP-induced iNOS-
derived nitrites, reversal of astrocyte death, reduced DA toxicity and stimulation 
of DA functional recovery, whereas OVX exacerbates astrocyte hypertrophy, 
microglia iNOS/NO generation and subsequent astrocyte and DA toxicity. These 
findings support a prominent protective role  for circulating sex steroids against 
MPTP-induced DA neurotoxicity, and further show an important effect of E2 
proestrous levels at the time of MPTP injection [25].  
 In summary, from the overall findings, it seems tempting to speculate that 
a causal relationship may exist between the exacerbation of glia reactivity of 
E2–deprived females and increased vulnerability of nigral DA neurons to 
MPTP, possibly implicating E2–induced switch of pro-inflammatory astroglial 
“Mr Hyde” into a “Dr Jekill” phenotype, as a determining factor in 
dopaminergic neuron protection. This complementary action of estrogen on 
astrocyte and microglia herein reviewed in the MPTP model of PD, may 
provide a potential pharmacological target and a new insight into the 
therapeutic potential of these hormones in Parkinson’s disease. 
 
Conclusion 
 In conclusion, although E2 is best known for its effects on the maturation and 
differentiation of the primary and secondary sex organs, increasing evidence 
clearly suggests that its influence extends beyond this system, and its activity in 
the CNS may initiate, or influence our susceptibility to neurodegenerative 
decline. Indeed, the overall accumulated evidence clearly underlines hormonal 
ability to act as a neuroprotectant at several levels. While E2 intrinsically 
produced within the brain may act as a survival and differentiation factor at 
selected perinatal time-windows, increased aromase expression in brain injured 
astrocytes coupled with the consequent increase of the hormone in specific 
lesioned-regions may significantly contribute to decreased neuronal vulnerability 
as well as to neuronal recovery and or repair.  Long-term deprivation of 
circulating E2 and a decrease of brain aromatase activity as a result of menopause 
exposes the aging or diseased brain to several insults, including increased 
risk/incidence of PD. In addition, E2 deprivation is likely to initiate or enhance a 
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pro-inflammatory status both at a systemic and central level.  Moreover, estrogen 
deficiency may be linked to the dysfunction of astrocyte and microglial 
compartments, with reduced ability of astrocytes to perform their crucial 
antioxidant and defensive functions, resulting in altered glial-neuron crosstalk. 
Decreased function of astroglial cells, e.g. as a result of increased 
oxidative/nitrosative stress, may lead to reduced expression of growth and 
neurotrophic factors, reduced scavenging properties and reduced anti-oxidant 
enzymes production, with consequent damage to neurons and inhibition of repair 
processes. With regard to the implication for PD, the findings herein reviewed in 
the MPTP model of PD suggest that endogenous E2 participate in the modulation 
of astrocyte and microglia reactivity and iNOS inducibility during 
neuroinflammation induced by MPTP. In particular, ovulatory E2 levels appear 
to contribute to restrain astroglial cell response to nitrosative stress, and 
consequently protect dopaminergic neurons against the described cytotoxic 
cascades, whereas estrogen deprivation sharply up-regulates various indices of 
astrocyte and microglia activation resulting in exacerbation of DA neurotoxicity. 
It seems interesting to notice that intact female mice appear more resistant when 
MPTP is administrated on proestrous, as compared to females treated at estrus. 
On the other hand, the hormonal background of estrus is able to significantly 
protect striatal indices of DA functionality against MPTP neurotoxicity as 
compared to OVX mice. Furthermore, intact female mice exhibit a significant 
degree of recovery from DA neurotoxicity, both at morphological and functional 
levels, thereby supporting a protective role for circulating ovarian hormones. 
 
 Given the crucial role of glia-neuron interactions in neuronal growth, survival 
differentiation and synapse formation, as well as in modulation of neurogenesis 
[124], alterations in glia-neuron crosstalk, as observed in E2-deprivation conditions, 
suggest a pivotal role for endogenous E2 in restraining harmful innate 
inflammatory reactions, thereby contributing to enhance astroglial neuroprotective 
functions and possibly helping the repair process (Fig. 3).  
 Consistently, it should be underlined, that while activation of innate immunity 
in the CNS accompanied  by     neurodegeration may         significantly impair neurogenesis, 
neuroinflammatory blockade and astrocyte “beneficial” activation can restore 
this crucial process [124-128]. In summary, the herein described estrogenic 
activation of glial anti-inflammatory and “protective” functions may provide a 
further mechanism reducing the detrimental effects of neuroinflammation, 
while promoting cytokine activation of astroglial “pro-regenerative” functions. 
This mechanism might represent a compensatory/adaptive response to 
stimulate the repair process (Fig. 3). Although the accumulating evidence from 
basic science studies using animal models suggests that E2 plays a critical 
neuroprotective role against multiple types of neurodegenerative diseases and 
injuries, recent  clinical studies have reported        either inconlusive or untoward side 
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Figure 3. Schematic representation of potential estrogen receptor/inducible-nitric oxide (iNO) 
crosstalk in glial neuroprotective functions. Stimulation of innate immunity has bidirectional 
effects on activated astroglial cells resulting in pro- and anti-inflammatory cascades with 
positive and negative influences on neuronal survival/protection/rescue. Activation of glial ER-
iNO crosstalk  may provide a further endogenous mechanism reducing neuroinflammatory 
detrimental effects, while promoting astroglial “pro-regenerative” functions [25]. 
 
effects of hormone therapy on the brain [46]. Indeed, results from the 
Women’s Health Initiative Memory Study (WHIMS) clinical trial have 
induced a reconsideration of the efficacy of estrogen hormone therapy as a 
strategy to prevent age-related cognitive decline and dementia, and a number 
of important issues, still remain unresolved, such as the timing and the duration 
of estrogen therapy as well as the combined presence of progestins. 
Development of selective receptor modulators for the brain  (SERMs), also 
called NeuroSERMs, certainly represent one major pharmacological challenge, 
to target E2-specific subtype receptors, in order to prevent brain-related 
climateric symptoms and neurodegnearative diseases [129-132]. The 
complementary action of estrogen on astrocyte and microglia herein reviewed 
in the MPTP model of PD, may provide a potential pharmacological target and 
a new insight into the therapeutic potential of these hormones in Parkinson’s 
disease,  and a further means to design “bifunctional” molecules aimed at 
preserving on the one hand astrocyte functionality while, on the other, 
restraining the aberrant stimulation of innate immunity. 
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